Leerink Partners Initiates Coverage On Lexeo Therapeutics with Outperform Rating, Announces Price Target of $19
Portfolio Pulse from Benzinga Newsdesk
Leerink Partners analyst Mani Foroohar has initiated coverage on Lexeo Therapeutics (NASDAQ:LXEO) with an Outperform rating and set a price target of $19.
November 28, 2023 | 1:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Leerink Partners initiated coverage on Lexeo Therapeutics with an Outperform rating and a price target of $19, which could positively influence investor sentiment and the stock's price.
Analyst ratings, especially initiations of coverage with positive outlooks, can lead to increased investor interest and a potential rise in stock price. The Outperform rating and the $19 price target suggest that Leerink Partners believes Lexeo Therapeutics has a favorable outlook, which may result in a short-term positive impact on the stock as the market reacts to the news.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100